Evaluation of ZAR1 and SFRP4 methylation status as potentials biomarkers for diagnosis in cervical cancer: exploratory study phase I. (May 2014)

• Record Type: Journal Article
• Authors: Brebi, Priscilla; Hoffstetter, Rene; Andana, Alejandra; Ili, Carmen G.; Saavedra, Kathleen; Viscarra, Tamara; Retamal, Javier; Sanchez, Raul; Roa, Juan C.
• Is Part Of: Biomarkers. Volume 19:Number 3(2014)
• Page Start: 181
• Page End: 188
• Publication Date: 2014-05
• Subjects: Biochemical markers -- Periodicals; 610.28
• DOI: 10.3109/1354750X.2013.867535
• Languages: English
• ISSNs: 1354-750X

Abstract

<abstract> <title>Abstract</title> <p> <italic>Context</italic>: Aberrant hypermethylation of promoter region of tumor suppressor genes could be used as cancer biomarkers.</p> <p> <italic>Objective</italic>: To test methylation status of <italic>ZAR1</italic> and <italic>SFRP4</italic> promoter regions as potentials biomarkers for diagnosis of preneoplastic and neoplastic lesions of cervix.</p> <p> <italic>Materials and methods</italic>: Cytobrush samples were evaluated by Methylation specific PCR (MSP) and quantitative MSP (qMSP).</p> <p> <italic>Results</italic>: <italic>ZAR1</italic> and <italic>SFRP4</italic> methylation frequency increased as the grade of lesion increased and the differences between normal and cervical cancer (CC) are statistically significant (<italic>p</italic> &lt; 0.0001). qMSP showed higher <italic>ZAR1</italic> and <italic>SFRP4</italic> methylation levels in cancer than normal epithelia (<italic>p</italic> &lt; 0.001) and preneoplastics lesions (<italic>p</italic> &lt; 0.01).</p> <p> <italic>Discussion</italic>: qMSP quantify methylation levels and have high sensitivity and specificity.</p> <p> <italic>Conclusion</italic>: <italic>ZAR1</italic> and <italic>SFRP4</italic> qMSP could be used as potential biomarker for CC diagnosis.</p> </abstract>